

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## **IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.



Coz

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/254,617
	Filing Date	March 22, 1999
	First Named Inventor	Jacques MALLET, et al.
	Art Unit	1632
	Examiner Name	Anne-Marie Falk
Total Number of Pages in This Submission	Attorney Docket Number	ST96025-US

Certificate

JUL 09 2004

of Correction

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Request for Cert. of Correction (1 pg); Cert. of Correction Form (1 page); copy of pages 1-7 from Amendment After Final (7 pages).
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Customer No. 29693

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David J. Kulik, Reg. No. 36,576
Signature	
Date	July 6, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	
Signature	Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUL 12 2004



PATENT  
Attorney Docket No.: ST96025-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jacques MALLET, et al.

**Patent. No.: 6,723,315 B1**  
**(Issued April 20, 2004)**

Application No. 09/254,617

For: METHOD FOR TREATING  
AMYOTROPHIC LATERAL SCLEROSIS

Group Art Unit: 1632

Examiner: Anne-Marie Falk

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 37 CFR 1.322(a)**

Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Applicants respectfully request a Certificate of Correction under 37 CFR 1.322(a) be entered in the above-identified patent. This request is being submitted to correct errors in the issued patent referenced above, as enumerated on the attached Certificate of Correction Form PTO/SB/44. We also attach copies of pages 1-7 from the Amendment After Final filed on October 2, 2003, providing the amended listing of claims to replace all prior versions of claims in this application. It is evident from the attached listing of claims that the errors in the issued patent arose through the fault of the Patent Office. Accordingly, Applicant does not believe any fees are required to process this request. However, in the event any fees are due or required, please charge the undersigned's Deposit Account No. 50-1129.

Respectfully submitted,  
**WILEY REIN & FIELDING LLP**

Date: July 6, 2004

By:

  
David J. Kulik, Reg. No. 36,576

**WILEY REIN & FIELDING LLP**  
Attn: Patent Administration  
1776 K Street, N.W.  
Washington, D.C. 20006  
**Telephone: 202.719.7000**  
**Facsimile: 202.719.7049**

JUL 12 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,723,315 B1  
DATED : April 20, 2004  
INVENTOR(S) : Jacques MALLET, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

Claim 5, line 53, change "adenoviruses adenovirus" to --adenovirus--.  
Claim 10, line 1, change "according to" to --of--.  
Claim 17, line 27, change "a cassette" to --cassette--.  
Claim 24, line 60, change "of transcriptional" to -- of a transcriptional--.  
Claim 29, line 4, change "comprises an a" to --comprises a--.  
Claim 49, line 55, change "factors" to --factor--.  
Claim 50, line 59, change "factor under the" to --factor.--.  
Claim 55, line 2, change "factors" to --factor--.  
Claim 56, line 4, change "factors" to --factor--.  
Claim 57, line 6, change "factors" to --factor--.  
Claim 58, line 8, change "factors" to --factor--.

MAILING ADDRESS OF SENDER:

WILEY REIN & FIELDING, LLP  
DAVID J. KULIK, REG. NO. 36,576  
ATTN: PATENT ADMINISTRATION  
1776 K STREET, NW  
WASHINGTON, D.C. 20006


PATENT NO. 6,723,315 B1

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUL 12 2004



COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/254,617 Confirmation No. 7283  
Applicant : Jacques MALLET  
Filed : March 22, 1999  
TC/A.U. : 1632  
Examiner : Anne Falk  
  
Docket No. : ST96025-US  
Customer No. : 29693

**Mail Stop AF**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AFTER FINAL**

Sir:

In response to the Final Office Action of January 28, 2003 (Paper No. 20), and the Advisory Action of September 10, 2003 (Paper No. 25), applicants request reconsideration. In addition, in order to place the application in better form for appeal or in condition for allowance, applicants request entry of the following amendments. Applicants previously filed a Notice of Appeal on July 28, 2003; therefore this response is timely filed.

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-63 canceled.

64. (previously presented) A pharmaceutical composition comprising two adenovirus vectors, wherein each vector comprises a nucleic acid encoding a different neurotrophic factor.
65. (currently amended) The pharmaceutical composition according to claim 64, wherein the vectors comprise an expression cassette ~~for the simultaneous expression of two different neurotrophic factors~~ having the coding sequences of two different neurotrophic factors and having sequences that provide for the simultaneous expression of the two different neurotrophic factors.
66. (previously presented) The pharmaceutical composition according to claim 64, wherein the neurotrophic factors are selected from GDNF, BDNF, CNTF and NT3.
67. (currently amended) The pharmaceutical composition according to claim 66, wherein the adenovirus vectors are two replication defective recombinant ~~adenoviruses~~ adenovirus vectors, and wherein one adenovirus vector comprises a nucleic acid encoding CNTF and one adenovirus vector comprises a nucleic acid encoding GDNF.
68. (currently amended) The pharmaceutical composition according to claim 66, wherein the adenovirus vectors are two replication defective recombinant ~~adenoviruses~~ adenovirus vectors, and wherein one adenovirus vector comprises a nucleic acid encoding GDNF and one adenovirus vector comprises a nucleic acid encoding NT3.
69. (currently amended) The pharmaceutical composition according to claim 66, wherein the adenovirus vectors are two replication defective recombinant ~~adenoviruses~~ adenovirus vectors, and wherein one adenovirus vector comprises a nucleic acid encoding BDNF and one adenovirus vector comprises a nucleic acid encoding NT3.
70. (previously presented) The pharmaceutical composition according to claim 64, in an injectable form.

71. (previously presented) The pharmaceutical composition according to claim 64, further comprising riluzole.
72. (previously presented) The pharmaceutical composition according to claim 71, in an injectable form.
73. (previously presented) The pharmaceutical composition of claim 64, wherein one of the neurotrophic factors is CNTF.
74. (previously presented) The pharmaceutical composition of claim 64, wherein one of the neurotrophic factors is BDNF.
75. (previously presented) The pharmaceutical composition of claim 64, wherein at least one adenovirus vector is a replication defective recombinant adenovirus vector.
76. (previously presented) A method of treating amyotrophic lateral sclerosis comprising administering to a subject by systemic administration a pharmaceutical composition comprising an adenovirus vector comprising a nucleic acid encoding a neurotrophic factor, wherein the treatment results in a reduction in progressive motor neuron degeneration in said subject.
77. (previously presented) A method of treating amyotrophic lateral sclerosis comprising administering to a subject by systemic administration a pharmaceutical composition comprising an adenovirus vector comprising a nucleic acid encoding a neurotrophic factor, wherein the treatment results in a reduction in progressive denervation in said subject.
78. (previously presented) The method of claim 76, wherein the reduction in progressive motor neuron degeneration is detectable by a change in the rate of loss of the number of myelinated fibers in a peripheral nervous tissue.
79. (previously presented) The method of claim 77, wherein the reduction in progressive denervation is detectable by electromyography.
80. (previously presented) The method of claim 76, wherein the adenovirus vector comprises an expression cassette comprising a nucleic acid encoding a neurotrophic factor under the control of a transcriptional promoter.
81. (previously presented) The method of claim 77, wherein the adenovirus vector comprises an expression cassette comprising a nucleic acid encoding a neurotrophic factor under the control of a transcriptional promoter.

82. (previously presented) The method of claim 78, wherein the adenovirus vector comprises an expression cassette comprising a nucleic acid encoding a neurotrophic factor under the control of a transcriptional promoter.
83. (previously presented) The method of claim 79, wherein the adenovirus vector comprises an expression cassette comprising a nucleic acid encoding a neurotrophic factor under the control of a transcriptional promoter.
84. (previously presented) The method of claim 76, wherein the adenovirus vector comprises two expression cassettes, wherein each cassette comprises a nucleic acid encoding a different neurotrophic factor under the control of a transcriptional promoter.
85. (previously presented) The method of claim 77, wherein the adenovirus vector comprises two expression cassettes, wherein each cassette comprises a nucleic acid encoding a different neurotrophic factor under the control of a transcriptional promoter.
86. (previously presented) The method of claim 78, wherein the adenovirus vector comprises two expression cassettes, wherein each cassette comprises a nucleic acid encoding a different neurotrophic factor under the control of a transcriptional promoter.
87. (previously presented) The method of claim 79, wherein the adenovirus vector comprises two expression cassettes, wherein each cassette comprises a nucleic acid encoding a different neurotrophic factor under the control of a transcriptional promoter.
88. (previously presented) The method of claim 76, wherein the neurotrophic factor is GDNF, CNTF, BDNF or NT3.
89. (previously presented) The method of claim 77, wherein the neurotrophic factor is GDNF, CNTF, BDNF or NT3.
90. (previously presented) The method of claim 78, wherein the neurotrophic factor is GDNF, CNTF, BDNF or NT3.
91. (previously presented) The method of claim 79, wherein the neurotrophic factor is GDNF, CNTF, BDNF or NT3.
92. (currently amended) The method of claim 76, wherein the adenovirus vector comprises ~~an~~ a bicistronic expression cassette comprising two nucleic acid sequences, wherein each nucleic acid sequence encodes a different neurotrophic factor ~~under the control of a single transcriptional promoter.~~



93. (previously presented) The method of claim 92, wherein the neurotrophic factors are selected from GDNF, CNTF, BDNF and NT3.
94. (previously presented) The method of claim 93, wherein the neurotrophic factors are CNTF and GDNF.
95. (currently amended) The method of claim 92, wherein the bicistronic expression cassette further comprises a transcriptional promoter, the promoter selected from a constitutive eucaryotic promoter or a viral promoter.
96. (previously presented) The method of claim 95, wherein the promoter is selected from a CMV, RSV, or adenovirus promoter.
97. (previously presented) The method of claim 76, wherein the systemic administration comprises intravenous administration.
98. (previously presented) The method of claim 77, wherein the systemic administration comprises intravenous administration.
99. (previously presented) The method of claim 78, wherein the systemic administration comprises intravenous administration.
100. (previously presented) The method of claim 79, wherein the systemic administration comprises intravenous administration.
101. (previously presented) The method of claim 76, further comprising administering riluzole.
102. (previously presented) The method of claim 77, further comprising administering riluzole.
103. (previously presented) The method of claim 78, further comprising administering riluzole.
104. (previously presented) The method of claim 79, further comprising administering riluzole.
105. (previously presented) The method of claim 84, further comprising administering riluzole.
106. (previously presented) The method of claim 85, further comprising administering riluzole.
107. (previously presented) The method of claim 88, further comprising administering riluzole.

108. (previously presented) The method of claim 89, further comprising administering riluzole.

109. (previously presented) A method of treating amyotrophic lateral sclerosis comprising administering to a subject by systemic administration a pharmaceutical composition comprising an adenovirus vector comprising a nucleic acid encoding a neurotrophic factor, wherein the treatment results in increased lifespan for said subject.

110. (previously presented) The method of claim 109, wherein the adenovirus vector comprises an expression cassette comprising a nucleic acid encoding a neurotrophic factor under the control of a transcriptional promoter.

111. (previously presented) The method claim 109, wherein the adenovirus vector comprises two expression cassettes, wherein each cassette comprises a nucleic acid encoding a different neurotrophic factor under the control of a transcriptional promoter.

112. (previously presented) The method of claim 109, wherein the neurotrophic factor is one of GDNF, CNTF, BDNF or NT3.

113. (currently amended) The method of claim 109, wherein the adenovirus vector comprises an a bicistronic expression cassette comprising two nucleic acid sequences, wherein each nucleic acid sequence encodes a different neurotrophic factor ~~under the control of a single transcriptional promoter~~.

114. (previously presented) The method of claim 111, wherein the neurotrophic factors are selected from GDNF, CNTF, BDNF and NT3.

115. (previously presented) The method of claim 111, wherein the neurotrophic factors are CNTF and GDNF.

116. (previously presented) The method of claim 110, wherein the transcriptional promoter is a constitutive eucaryotic or viral promoter.

117. (previously presented) The method of claim 116, wherein the promoter is selected from a CMV, RSV, or adenovirus promoter.

118. (previously presented) The method of claim 109, wherein the neurotrophic factor is CNTF.

119. (previously presented) The method of claim 109, wherein the neurotrophic factor is GDNF.

120. (previously presented) The method of claim 109, wherein the neurotrophic factor is BDNF

121. (previously presented) The method of claim 109, wherein the neurotrophic factor is NT3.

122. (previously presented) The method of claim 109, further comprising administering riluzole.

123. (previously presented) The method of claim 111, further comprising administering riluzole.

124. (previously presented) The method of claim 112, further comprising administering riluzole.

125. (previously presented) The method of claim 109, wherein the systemic administration comprises intravenous administration.

126. (previously presented) The method of claim 111, wherein the systemic administration comprises intravenous administration.

127. (previously presented) The method of claim 112, wherein the systemic administration comprises intravenous administration.

128. (previously presented) The method of claim 122, wherein the systemic administration comprises intravenous administration.